Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
종목 코드 NXLIW
회사 이름Nexalin Technology Inc
상장일Sep 16, 2022
CEOMr. Mark White
직원 수- -
유형Company Warrant
회계 연도 종료- -
주소1776 Yorktown
도시HOUSTON
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호77056
전화18322600222
웹사이트https://nexalin.com
종목 코드 NXLIW
상장일Sep 16, 2022
CEOMr. Mark White
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음